441 filings
Page 6 of 23
6-K
CLLS
Cellectis
1 Aug 22
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
4:30pm
6-K
CLLS
Cellectis
28 Jul 22
Cellectis to Report Second Quarter 2022 Financial Results
4:36pm
EFFECT
CLLS
Cellectis
8 Jul 22
Notice of effectiveness
12:15am
CORRESP
CLLS
Cellectis
5 Jul 22
Correspondence with SEC
12:00am
6-K
CLLS
Cellectis
30 Jun 22
Current report (foreign)
6:31am
UPLOAD
CLLS
Cellectis
29 Jun 22
Letter from SEC
12:00am
6-K
CLLS
Cellectis
28 Jun 22
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
4:45pm
6-K
CLLS
Cellectis
28 Jun 22
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting
4:17pm
F-3
CLLS
Cellectis
24 Jun 22
Shelf registration (foreign)
4:19pm
POSASR
CLLS
Cellectis
24 Jun 22
Automatic shelf registration (post-effective amendment)
4:14pm
6-K
CLLS
Cellectis
23 May 22
Cellectis’ Annual Shareholders’ General Meeting to be Held
4:46pm
6-K
CLLS
Cellectis
23 May 22
Current report (foreign)
7:54am
6-K
CLLS
Cellectis
16 May 22
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
8:15am
6-K
CLLS
Cellectis
12 May 22
Current report (foreign)
4:48pm
6-K
CLLS
Cellectis
12 May 22
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
4:40pm
6-K
CLLS
Cellectis
5 May 22
Cellectis to Report First Quarter 2022 Financial Results
12:00am
6-K
CLLS
Cellectis
5 May 22
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
12:00am
SC 13G
Long Focus Capital Management, LLC
3 May 22
Cellectis / Long Focus Capital Management ownership change
2:15pm
6-K
CLLS
Cellectis
28 Apr 22
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
8:00am
6-K
CLLS
Cellectis
27 Apr 22
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
6:31am